Company Description
Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States.
The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand.
It also develops VYD2311, a monoclonal antibody, which is in Phase III clinical trial for the prevention and treatment of SARS-CoV-2 virus; and VBY329, a monoclonal antibody, which is in pre-clinical trial stage for the prevention and treatment of respiratory syncytial virus and measles in neonates, infants, and children.
It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies.
The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022.
Invivyd, Inc. was incorporated in 2020 and is headquartered in New Haven, Connecticut.
| Country | United States |
| Founded | 2020 |
| IPO Date | Aug 6, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 122 |
| CEO | William Duke |
Contact Details
Address: 209 Church Street New Haven, Connecticut 06510 United States | |
| Phone | 781 819 0080 |
| Website | invivyd.com |
Stock Details
| Ticker Symbol | IVVD |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001832038 |
| CUSIP Number | 00534A102 |
| ISIN Number | US00534A1025 |
| Employer ID | 85-1403134 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| William E. Duke Jr., M.B.A. | Chief Financial Officer, Principal Accounting Officer and Principal Executive Officer |
| Jill Andersen J.D. | Chief Legal Officer and Corporate Secretary |
| Timothy Lee | Chief Commercial Officer |
| Dr. Robert D. Allen Ph.D. | Chief Scientific Officer |
| Kristie Coneys Kuhl J.D. | Chief Communications Officer |
| Julie Green M.B.A. | Chief Human Resources Officer |
| Rachael Gerlach Ph.D. | Senior Vice President of Regulatory Affairs |
| Katie Falzone CPA | Senior Vice President of Finance |
| Dr. Michael J. Mina M.D., Ph.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 9, 2026 | 8-K | Current Report |
| Apr 6, 2026 | ARS | Filing |
| Apr 6, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 6, 2026 | DEF 14A | Other definitive proxy statements |
| Mar 5, 2026 | 10-K | Annual Report |
| Mar 5, 2026 | 8-K | Current Report |
| Feb 17, 2026 | 144 | Filing |
| Feb 17, 2026 | 144 | Filing |
| Feb 17, 2026 | 144 | Filing |
| Feb 17, 2026 | 144 | Filing |